Inventor · disambiguated record
Tanja Fauti
Also filed as: FAUTI TANJA
10 granted patents·23 pending applications·62 citations·filing 2012–2024
87Inventor score
Top patents by PatentIndex Score
33 records- 0192US11608376B2Tumor-targeted agonistic CD28 antigen binding moleculesHOFFMANN LA ROCHE·Filed 2019·Granted Mar 21, 2023·14 cites·49 claims
- 0292US9963513B2Method for the selection of antibodies against BCMAENGMAB AG·Filed 2014·Granted May 8, 2018·19 cites·5 claims
- 0388US2025043028A1Bispecific t cell activating antigen binding moleculesROCHE GLYCART AG·Filed 2024·Application pending·0 cites
- 0487US10253104B2Bispecific antibodies against CD3ϵ and BCMAENGMAB AG·Filed 2015·Granted Apr 9, 2019·10 cites·16 claims
- 0587US10087250B2Fc-free antibodies comprising two fab-fragments and methods of useROCHE GLYCART AG·Filed 2013·Granted Oct 2, 2018·10 cites·12 claims
- 0686US2024425616A1Bispecific t cell activating antigen binding moleculesROCHE GLYCART AG·Filed 2024·Application pending·0 cites
- 0784US10077315B2Bispecific antibodies against CD3 and BCMAENGMAB AG·Filed 2014·Granted Sep 18, 2018·6 cites·5 claims
- 0884US2023340160A1Bispecific t cell activating antigen binding moleculesROCHE GLYCART AG·Filed 2023·Application pending·0 cites
- 0983US11987632B2Antibodies binding to HLA-A2/MAGE-A4HOFFMANN LA ROCHE·Filed 2020·Granted May 21, 2024·1 cites·68 claims
- 1080US10851171B2Method for the selection of antibodies against BCMAENGMAB SARL·Filed 2018·Granted Dec 1, 2020·1 cites·4 claims
- 1176US2024383987A1Antibodies binding to hla-a2/mage-a4HOFFMANN LA ROCHE·Filed 2024·Application pending·0 cites
- 1275US10766967B2Bispecific T cell activating antigen binding moleculesHOFFMANN LA ROCHE·Filed 2016·Granted Sep 8, 2020·1 cites·50 claims
- 1369US2023355754A1Combination therapy of tumor targeted icos agonists with t-cell bispecific moleculesHOFFMANN LA ROCHE·Filed 2023·Application pending·0 cites
- 1468US2021070873A1Method for the selection of antibodies against bcmaENGMAB SARL·Filed 2020·Application pending·0 cites
- 1562US11639397B2Bispecific antibodies specific for T-cell activating antigens and a tumor antigen and methods of useROCHE GLYCART AG·Filed 2014·Granted May 2, 2023·0 cites·13 claims
- 1662US2018273643A1Bispecific t cell activating antigen binding moleculesROCHE GLYCART AG·Filed 2018·Application pending·0 cites
- 1761US2024043535A1IMMUNE ACTIVATING Fc DOMAIN BINDING MOLECULESHOFFMANN LA ROCHE·Filed 2022·Application pending·0 cites
- 1860US2020347147A1Bispecific t cell activating antigen binding moleculesHOFFMANN LA ROCHE·Filed 2020·Application pending·0 cites
- 1957US2013078249A1Bispecific t cell activating antigen binding moleculesAST OLIVER·Filed 2012·Application pending·0 cites
- 2057US2020306373A1Combination therapy of tumor targeted icos agonists with t-cell bispecific moleculesHOFFMANN LA ROCHE·Filed 2020·Application pending·0 cites
- 2156US2020255521A1Bispecific antibodies against cd3epsilon and ror1ENGMAB SARL·Filed 2020·Application pending·0 cites
- 2256US2022098305A1Novel icos antibodies and tumor-targeted antigen binding molecules comprising themHOFFMANN LA ROCHE·Filed 2021·Application pending·0 cites
- 2355US2022259318A1Antibodies binding to gprc5dHOFFMANN LA ROCHE·Filed 2022·Application pending·0 cites
- 2450US2016297881A1BISPECIFIC ANTIBODIES AGAINST CD3EPSILON and ROR1ENGMAB AG·Filed 2014·Application pending·0 cites
- 2547US2013058936A1Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of useBRUENKER PETER·Filed 2012·Application pending·0 cites
- 2646US11952421B2Bispecific antibodies against CD3EPSILON and ROR1BRISTOL MYERS SQUIBB CO·Filed 2015·Granted Apr 9, 2024·0 cites·6 claims
- 2746US2017198043A1Bispecific antigen binding moleculesROCHE GLYCART AG·Filed 2016·Application pending·0 cites
- 2843US2013058937A1Bispecific antigen binding moleculesAUER JOHANNES·Filed 2012·Application pending·0 cites
- 2943US2017114146A1Bispecific T cell activating antigen binding moleculesHOFFMANN LA ROCHE·Filed 2016·Application pending·0 cites
- 3041US2013078250A1Bispecific t cell activating antigen binding moleculesAST OLIVER·Filed 2012·Application pending·0 cites
- 3140US2017096485A1Bispecific t cell activating antigen binding moleculesHOFFMANN LA ROCHE·Filed 2016·Application pending·0 cites
- 3234US2017327579A1Bispecific antibodies against cd3epsilon and bcmaENGMAB AG·Filed 2015·Application pending·0 cites
- 3333US2017306044A1Bispecific antibodies against cd3epsilon and ror1 for use in the treatment of ovarian cancerENGMAB AG·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Tanja Fauti files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →